Boris Y. Alekseev
Moscow, MOW, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications
Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: May 24, 2026
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Journal: Nature medicine
Published: July 21, 2025
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
Journal: European urology
Published: July 14, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.
Journal: JAMA network open
Published: May 07, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Journal: Nature medicine
Published: January 22, 2025
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.
Journal: Frontiers in molecular biosciences
Published: November 20, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 16, 2024
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Journal: European urology
Published: December 09, 2023
Assessing the Efficacy of Anti-Cancer Drugs on Organoid Models Derived from Prostate Cancer.
Journal: Doklady. Biochemistry and biophysics
Published: December 01, 2023
Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
Journal: Bulletin of experimental biology and medicine
Published: November 02, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Journal: European urology open science
Published: October 05, 2023
Last Updated: 09/26/2026